Total Payments
$85,073
2024 Payments
$1,174
Companies
49
Transactions
874
Medicare Patients
3,700
Medicare Billing
$710,729
Payment Breakdown by Category
Other$50,565 (59.4%)
Food & Beverage$15,008 (17.6%)
Consulting$12,230 (14.4%)
Travel$6,757 (7.9%)
Gifts$506.40 (0.6%)
Education$6.02 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48,815 | 32 | 57.4% |
| Food and Beverage | $15,008 | 781 | 17.6% |
| Consulting Fee | $12,230 | 9 | 14.4% |
| Travel and Lodging | $6,757 | 48 | 7.9% |
| Honoraria | $1,750 | 2 | 2.1% |
| Gift | $506.40 | 1 | 0.6% |
| Education | $6.02 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US WorldMeds, LLC | $34,856 | 109 | $0 (2020) |
| Alkermes, Inc. | $21,737 | 70 | $0 (2024) |
| Orexo US, Inc. | $10,431 | 82 | $0 (2024) |
| Gilead Sciences, Inc. | $7,899 | 53 | $0 (2024) |
| ABBVIE INC. | $2,093 | 117 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,082 | 69 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $809.61 | 44 | $0 (2024) |
| USWM, LLC | $799.45 | 19 | $0 (2022) |
| Novo Nordisk Inc | $432.01 | 5 | $0 (2019) |
| Allergan, Inc. | $389.04 | 30 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,174 | 60 | ABBVIE INC. ($372.77) |
| 2023 | $725.99 | 44 | ABBVIE INC. ($216.14) |
| 2022 | $1,716 | 68 | USWM, LLC ($522.35) |
| 2021 | $1,916 | 117 | AbbVie Inc. ($543.67) |
| 2020 | $3,646 | 109 | US WorldMeds, LLC ($2,093) |
| 2019 | $26,546 | 153 | US WorldMeds, LLC ($12,114) |
| 2018 | $29,361 | 187 | US WorldMeds, LLC ($20,649) |
| 2017 | $19,987 | 136 | Alkermes, Inc. ($8,655) |
All Payment Transactions
874 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Central Nervous System | ||||||
| 12/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: PSYCHIATRY | ||||||
| 12/02/2024 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $17.57 | General |
| Category: Addiction Medicine | ||||||
| 11/29/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: RESPIRATORY | ||||||
| 11/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.37 | General |
| 11/14/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.29 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Neuropsychiatry | ||||||
| 11/04/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: CNS | ||||||
| 10/31/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: PSYCHIATRY | ||||||
| 10/28/2024 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $18.40 | General |
| Category: Addiction Medicine | ||||||
| 10/22/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $1.56 | General |
| Category: VIROLOGY | ||||||
| 10/10/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Central Nervous System | ||||||
| 09/26/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: PSYCHIATRY | ||||||
| 09/17/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.61 | General |
| Category: PSYCHIATRY | ||||||
| 09/13/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $4.44 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2024 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $17.40 | General |
| Category: Addiction Medicine | ||||||
| 08/26/2024 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $16.16 | General |
| Category: Addiction Medicine | ||||||
| 08/22/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $25.99 | General |
| Category: CNS | ||||||
| 08/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: RESPIRATORY | ||||||
| 08/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Central Nervous System | ||||||
| 08/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: NEUROSCIENCE | ||||||
| 08/05/2024 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $17.53 | General |
| Category: Addiction Medicine | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 717 | 2,041 | $280,080 | $154,303 |
| 2022 | 16 | 884 | 2,290 | $321,195 | $174,095 |
| 2021 | 16 | 942 | 2,607 | $359,685 | $197,970 |
| 2020 | 16 | 1,157 | 2,871 | $356,045 | $184,361 |
Total Patients
3,700
Total Services
9,809
Medicare Billing
$710,729
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 112 | 663 | $112,490 | $62,058 | 55.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 93 | 668 | $86,840 | $42,523 | 49.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 97 | 140 | $21,000 | $12,962 | 61.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 68 | 150 | $18,180 | $9,711 | 53.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 35 | 70 | $9,800 | $6,396 | 65.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 47 | 47 | $8,460 | $6,096 | 72.1% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 12 | 13 | $4,030 | $2,882 | 71.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $4,080 | $2,494 | 61.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 18 | $3,860 | $2,337 | 60.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 95 | 95 | $2,850 | $1,710 | 60.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 22 | 22 | $1,760 | $1,662 | 94.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 40 | 40 | $1,400 | $1,250 | 89.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 13 | 23 | $2,990 | $1,117 | 37.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 38 | $1,140 | $406.08 | 35.6% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 18 | 18 | $540.00 | $368.28 | 68.2% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 22 | 22 | $660.00 | $330.22 | 50.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 121 | 683 | $109,380 | $63,856 | 58.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 122 | 730 | $95,095 | $41,379 | 43.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 237 | $26,070 | $15,694 | 60.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 70 | 83 | $26,975 | $12,643 | 46.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 62 | 101 | $14,140 | $8,483 | 60.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 49 | 49 | $8,860 | $6,506 | 73.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 67 | 79 | $11,850 | $6,405 | 54.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 18 | 25 | $7,750 | $5,648 | 72.9% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 17 | 19 | $4,940 | $3,190 | 64.6% |
About Dr. Michael Fox, D.O
Dr. Michael Fox, D.O is a Addiction Medicine healthcare provider based in Livonia, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558444711.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Fox, D.O has received a total of $85,073 in payments from pharmaceutical and medical device companies, with $1,174 received in 2024. These payments were reported across 874 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($48,815).
As a Medicare-enrolled provider, Fox has provided services to 3,700 Medicare beneficiaries, totaling 9,809 services with total Medicare billing of $710,729. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Location Livonia, MI
- Active Since 10/23/2006
- Last Updated 03/05/2015
- Taxonomy Code 207QA0401X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558444711
Products in Payments
- Lucemyra/Lofexidine (Drug) $34,238
- Vivitrol 380 mg (Drug) $11,373
- Zubsolv (Drug) $10,431
- VIVITROL (Drug) $10,196
- Vosevi (Drug) $4,374
- AUSTEDO (Drug) $742.17
- UBRELVY (Drug) $691.27
- VRAYLAR (Drug) $556.26
- Epclusa (Drug) $525.00
- ZIMHI (Drug) $506.40
- MAVYRET (Drug) $498.35
- FARXIGA (Drug) $453.96
- Mavyret (Drug) $410.36
- INGREZZA (Drug) $366.75
- LATUDA (Drug) $332.45
- Lucemyra (Drug) $315.54
- SUNOSI (Drug) $289.35
- QULIPTA (Drug) $264.56
- Austedo XR (Drug) $245.60
- TROKENDI XR (Drug) $240.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.